Thanks Amir.
now discontinued to remind Instrument third as of Before we I results Accordingly, are Business on reported based quarterly sale business. Unit the quarter and Treatment pending that are Unit of reflecting Treatment KaVo would begin, Instrument and operations. the continuing our operations, our the results you KaVo like
moment this for discontinuing are performing continuing exceeded complexity, both into in Results that operations quarter. of our I confirm diving expectations to before just like Given continuing level and and take our results well. very businesses the to our operations, operations a the would set
to We confidence full are to invest have ahead our guidance of continuing while we raise guidance and the our on our based long the performance, term. year for
the to moving results Now the in quarter.
currency Reported rates exchange Third were impacted quarter X.X% foreign other discontinued XX% and to X.X% sales due products. $XXX.X negatively related increased to impacted to positively million. sales
to sales of compared core third growth the XX.X% XXXX. Our quarter was
X.X%, respectively, quarter and improve As market X.X% portfolio. and business Amir growth core continued Geographically, of conditions sales dental and XXXX. was the demand solid across year-over-year third our execution compared our across consistent growth to America reflects Western Europe's discussed, North to as the
we In rebounding solid grew emerging solutions. Our including from as markets, emerging China, business are orthodontic our Outside both continue quarter. lows. over to clearly pandemic in China, markets our see well of growth other important XX% as implant strategically our in China, the
of optimistic We markets continue balance demand roll continue the for we into volume pre-pandemic see about Overall, to Barring of believe we to XXXX. the balance major in levels overall the expect these volumes above any demand XXXX. or to continued to will vaccinations out for remain strengthening either economies as the and patient remain XXXX pandemic-related disruptions chain, that reopen. supply of and
quarter XX productivity margin volume, of due third by higher adjusted continuing points our XXX the from which points EBITDA to basis basis product year gross lower increasing mix operations initiatives favorable was across margins than to XX.X%, Our QX The portfolio. was XXXX. XX.X%, prior of compared and
innovation As with lockdowns. invest term the expected, activities in easing on to in-person we pandemic-related continued spending QX of long travel increasing customer-facing in and our continued while
Our costs the adjusted related and Instrument KaVo in to million stranded sale negatively by Treatment impacted business. the was of approximately expected EBITDA Unit $X
addressing of our $XX million We stranded approximately begin expect QX. to in costs annualized
from compared from quarter continuing third $X.XX to adjusted the $X.XX year. EPS operations prior Our was
by and products technologies from technologies XXXX, in to XXXX, third segment and products of implants to the our Our growth growth XX.X% revenue of quarter compared continued XX.X%. increased strong core and premium the quarter Compared growth segment specialty driven specialty core third was Spark. by
across execution and growth we saw solid are share improving implant the to premium premium core led in believe Our business most double XXXX. versus growth geographies digit in segment. gaining We
XXX quarter margin basis technologies and profit specialty our higher results. operating XX.X% was third Our products XXXX points adjusted at than segment
by Our customer-facing and spending growth, as activities and improved profitability primarily in on favorable investments term long innovation. as offset by savings driven well structural increased mix product solid travel was cost
to Our of third in XX% segment demand X% core compared increased from compared quarter over equipment XXXX. with and in Strong XXXX. to results and imaging sales the consumables continuing business of solid third growth this the drove our segment execution operations core quarter
lower the Despite share dental of infection sales, and trends sales our we distributors QX core that our from declined market expected, peak demand. indicate solutions our gaining medical are As by inventory markets. prevention sellout pandemic reported in
consumables single well CaviWipes and XX.X% demand should we the Additionally, XXXX. see protocols Overall, the capture has driving us this and term of margin continuing Equipment and in business XX.X% expect quarter adjusted versus future. share. market help to mid additional been enhanced operating received third X.X profit in digits higher in safety continue grow in to the operations was XXXX from long
commodities Solid prevention Further, restorative offset our we to solutions infection slowdown chemical inflation prevention. margin business. experienced imaging that in improvement some in the and by was related infection impacted
higher long sale margin Amir the business and Unit our As the consumables noted, equipment KaVo will and and pending Instrument Treatment Business, faster be business term. over of growth with
For with KaVo the over Instrument expected the cash Business and $XXX excluding sale. generated of ended third flow the Unit in million quarter proceeds the cash million Treatment and we $XX.X quarter, from free
liquidity as opportunities is to sheet pursue ample inorganic available. balance and they growth very Our we strong become have
We and expecting forward EBITDA continuing million of to million. Business. stranded KaVo associated $XXX deliver This with raising from XXXX, negative and to Treatment year billion includes adjusted of and we impact now approximately between Instrument between revenue further are the a $X.XXX Unit are costs $X.X million full of year and $XX billion. $XXX operations sale to full deliver Looking expect guidance our
these addressing XXXX. to costs impact move As QX through reduce and mentioned, work as we we in begin expect to the
our early our over term too to is by it increasing guidance initiatives. annually I for basis some call growth, remain we the comments. margins while for will delivering XX our operating single long term points While funding target to Amir turn committed growth to provide XXXX, closing long XX of to mid digit